Brief: Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus
23/12/2025 11:02
Dec 23 (Reuters) - Nanjing Leads Biolabs 9887.HK: LEADS BIOLABS AND DIANTHUS THERAPEUTICS ANNOUNCE INITIATION OF PHASE 1 TRIAL OF LBL-047 (DNTH212) IN HEALTHY VOLUNTEERS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) NANJING LEADS BIOLABS CO LTD: TOP-LINE RESULTS IN HEALTHY VOLUNTEERS ANTICIPATED IN 2H'26 Source text: ID:nGNX5742Sr Further company coverage: 9887.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanjing Leads Biolabs
See all newsBrief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer